Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy
Key facts
- Who runs it
- Centre Hospitalier Universitaire, Amiens
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 200 people, planned
- Started
- 14 Jan 2025
- Ended
- Aug 2025
- Type of study
- Observational
- Record updated
- 19 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age : > 18 years old
- Uveitis requiring immunosuppressive therapy
- Including at least one posterior involvement according to the SUN terminology: posterior, or intermediate and posterior, or anterior and posterior, or panuveitis
Who cannot take part
- Ocular involvement in Behcet's disease requiring biologic therapy as first-line immunosuppressive treatment
- Uveitis associated with multiple sclerosis or systemic lupus erythematosus
- Uveitis without posterior segment involvement
- Infectious uveitis
- Patients objecting to the use of their personal data for research purposes
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Uveitis is an inflammatory disease of the uvea, constituting the 4th leading cause of legal blindness worldwide and the 3rd leading cause of avoidable blindness . It is not a rare condition, with an incidence of 17 to 52 per 100,000 population and a prevalence of 38 to 204 per 100,000 population. In the case of cortico-dependence, it is generally accepted to propose sparing with a conventional immunosuppressant, whose efficacy is estimated at around 70%, compared with biotherapies, which are considered more effective (over 90%) but only available as 2nd-line treatment. However, there are few studies on the failure factors of this first-line treatment, such as macular thickness , gender, or vitamin D deficiency. Risk factors for flare-ups are nevertheless known, notably ethnicity, and smoking. The aim of this study is to identify risk factors for treatment failure after three months of first-line immunosuppressive therapy in patients with chronic non-infectious uveitis at Amiens-Picardie University Hospital.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 19 March 2025